Completely satisfied Thanksgiving Eve from STAT reporter Andrew Joseph, filling in for the day. A observe that this text is taking a break Thursday and Friday, one thing to be glad about certainly. Now, the right way to go away you earlier than the massive day? Sir Pharmalot himself instructed we make a point out of the place turkey futures stand this morning, in case anybody is attempting to attain a last-minute turkey at cut price costs. As a substitute, we’re extra targeted on gaming out our oven technique for the massive meal, with a selected precedence on the pecan pie we’re on faucet for. We’re, in spite of everything, a former winner of STAT’s pie contest, so we’ve a status to uphold. Just a few extra items of knowledge as we head into the vacation: Heat up appropriately for each your turkey trots and turkey feasts — we don’t need any accidents on the market. Salads completely have a spot on the Thanksgiving desk (you want one thing vivid and acidic to chop via all the pieces else that’s wealthy and fatty; cranberry sauce shouldn’t must shoulder that accountability alone). And at last, regardless of how full you get, there’s all the time room for dessert — and sure, for an additional serving to of gratitude. Benefit from the vacation.
The U.S. Meals and Drug Administration on Tuesday authorized the primary gene remedy to deal with individuals with hemophilia B, an inherited bleeding dysfunction, STAT writes. The one-time remedy, referred to as Hemgenix, was developed by the Dutch biotech firm UniQure and might be marketed by CSL Behring, an Australian pharmaceutical firm. Hemgenix will value $3.5 million, making it the costliest drug authorized so far. The approval of Hemgenix gives physicians with a brand new, doubtlessly healing remedy choice for sufferers with extreme hemophilia B, a uncommon bleeding dysfunction attributable to a genetic mutation that stops the physique from producing enough portions of a clotting protein referred to as Issue IX.